drugset / Trial / NCT06022250
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Phase 1
Active not recruiting
98 enrolled
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH · collab
NaSequentialOpen-labelTreatment
Summary
This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK),Pharmacodynamic characteristics, immunogenicity and antitumor activity of JS207 in patients with advanced malignant tumor. The Recommended dose for phase II trial （RP2D） will be determined based on the safety, tolerability, pharmacokinetics.
Timeline
- Start
- 2023-09-26
- Primary completion
- 2026-04-08
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS207 | Monoclonal antibody | — | Intravenous |